Sofosbuvir

Drug Profile

Sofosbuvir

Alternative Names: GS-7977; HEPCINAT; Hepcvir; P-7977; PSI-7977; Sovaldi; SoviHep

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Pharmasset
  • Developer Bristol-Myers Squibb; Gilead Sciences
  • Class Antivirals; Phosphoric acid esters; Pyrimidine nucleotides; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 26 May 2017 Bristol-Myers Squibb completes a phase III trial for genotype 3 chronic Hepatitis C (Combination therapy) in USA, Canada (PO) (NCT02673489)
  • 08 Apr 2017 Launched for Hepatitis C (Combination therapy, In adolescents) in USA (PO)
  • 07 Apr 2017 Registered for Hepatitis C (Combination therapy, In adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top